Li Zhenfei
Professor
Biochemistry and Cell Biology
Shanghai Institutes for Biological Sciences
China
Biography
LI Zhenfei is a Professor of Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, hanghai, China. Research Areas: Androgen metabolism in castration resistant prostate cancer. Research Interests: Prostate cancer is the most common cancer in man and castration resistant prostate cancer (CRPC) is lethal. Hormone therapy by inhibiting androgen receptor signaling is one major treatment plan for CRPC patients. We focus on steroidogenesis and drug metabolism to unveil drug resistant mechanisms and discover novel targets for treatment or biomarkers for prognosis. Specifically, we are interested in these areas: 1. Drug metabolism and its application in clinic; 2. Drug resistant mechanisms and new target for therapy; 3. Crosstalk between AR signaling and other signalings in CRPC; 4. Hormone metabolism in other cancers.
Research Interest
Prostate cancer is the most common cancer in man and castration resistant prostate cancer (CRPC) is lethal. Hormone therapy by inhibiting androgen receptor signaling is one major treatment plan for CRPC patients. We focus on steroidogenesis and drug metabolism to unveil drug resistant mechanisms and discover novel targets for treatment or biomarkers for prognosis. Specifically, we are interested in these areas: 1. Drug metabolism and its application in clinic; 2. Drug resistant mechanisms and new target for therapy; 3. Crosstalk between AR signaling and other signalings in CRPC; 4. Hormone metabolism in other cancers.
Publications
-
Mohammad Alyamani, Zhenfei Li, Sunil K Upadhyay, David J Anderson, Richard J Auchus, Nima Sharifi. Development and validation of a novel LC–MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column. J Steroid Biochem Mol Biol, doi: 10.1016. (2016).
-
Zhenfei Li, Andrew Bishop, Mohammad Alyamani, Jorge A. Garcia, Robert Dreicer, Dustin Bunch, Jiayan Liu, Sunil K. Upadhyay, Richard J. Auchus, Nima Sharifi. Conversion of abiraterone to D4A drives antitumor activity in prostate cancer. Nature. 523, 347-351 (2015).
-
Zhenfei Li, Mohammad Alyammani, Jianneng Li, Kevin Rogacki, Mohamed Abazeed, Sunil Upadhyay, Steven P. Balk, Mary-Ellen Taplin, Richard J. Auchus, Nima Sharifi. Redirecting abiraterone metabolism to biochemically fine tune prostate cancer therapy. Nature. 533, 547-551 (2016).
